Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis;Malignome und Tumor-Nekrose-Faktor-Inhibitoren bei der juvenilen idiopathischen Arthritis

Zeitschrift fur Rheumatologie

Volumn 69, Issue 6, 2010, Pages 516-526

  Horneff, G ^a  

^a Asklepios Kinderklinik St Augustin GmbH   (Germany)

Author keywords

Adalimumab; Etanercept; Infliximab; Juvenile idiopathic arthritis; Malignancy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HODGKIN DISEASE; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MALE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; REVIEW; THYROID CANCER; UTERINE CERVIX DYSPLASIA; YOLK SAC TUMOR;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA; LYMPHOMA; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956339259     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-010-0655-8     Document Type: Review

References (28)

1. Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414-1420
2. Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692-701
3. Cucchiara S, Escher JC, Hildebrand H et al (2009) Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 48:257-267
4. Franklin J, Lunt M, Bunn D et al (2006) Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65:617-622
5. GEKID (2008) Cancer in Germany, 6th edn. http://www.ekr.med.uni-erlangen. de/GEKID/Doc/kid2008-english.pdf
6. Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794-2804
7. Hellgren K, Iliadou A, Rosenquist R et al (2010) Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 69:654-659
8. Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 68:519-525
9. Horneff G, Schmeling H, Biedermann T et al (2004) The German Etanercept Registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 63:1638-1644
10. Kaatsch P (2008) Jahresbericht Kinderkrebsregister. http://www. kinderkrebsregister.de
11. Klein A, Horneff G (2009) Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 10:3049-3060
12. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769
13. Lovell DJ, Reiff A, Jones OY et al (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54:1987-1994
14. Lovell DJ, Ruperto N, Goodman S et al (2008) Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810-820
15. Mackey AC, Green L, Leptak C, Avigan M (2009) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 48:386-388
16. Mackey AC, Green L, Liang LC et al (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44:265-267
17. Minden K, Niewerth M, Listing J et al (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:2392-2401
18. Prince FH, Twilt M, Ten Cate R et al (2008) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch National Register. Ann Rheum Dis 68:635-641
19. Ruperto N, Lovell DJ, Cuttica R et al (2007) Pediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group: a randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096-3106
20. Ruperto N, Ravelli A, Castell E et al (2006) Cyc- losporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing sur- veillance study. Clin Exp Rheumatol 5:599-605
21. Sandlund JT, Downing JR, Crist WM (1996) Non- Hodgkins lymphoma in childhood. N Engl J Med 334:1238-1248
22. Trapani S, Grisolia F, Simonini G et al (2000) Inci- dence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum 29:348-359
23. U.S. Food and Drug Administration (2008) Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). ht- tp://www.fda.gov/Drugs/DrugSafety/ Postmarket- DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm070725.htm
24. U.S. Food and Drug Administration (2009) Information for Healthcare Professionals: Tumor Necrosis Factor (TNF) Blockers (marketed as Remica de, Enbrel, Humira, Cimzia, and Simponi). http:// www.fda.gov/Drugs/DrugSafety/ Postmarket- DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm174474.htm
25. U.S. Food and Drug Administration (2009b) Ques- tions and Answers - TNF Blockers 8/25/2009. ht- tp://www.fda.gov/Drugs/DrugSafety/Postmarket- DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm180694.htm
26. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Ar- thritis Rheum 56:2886-2895
27. Woo P, Wedderburn LR (1998) Juvenile chronic ar- thritis. Lancet 351:969-973
28. Yildirim-Toruner C, Kimura Y, Rabinovich E (2008) Hodgkins lymphoma and tumor necrosis factor in- hibitors in juvenile idiopathic arthritis. J Rheuma- tol 35:1680-1681